



August 31, 2017

Regeneron Announces Upcoming Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 31, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows:

- | Morgan Stanley Annual Global Healthcare Conference at 11:40 a.m. ET on Monday, September 11, 2017
- | Bank of America Merrill Lynch Global Healthcare Conference at 5:40 a.m. ET (10:40 a.m. BST) on Wednesday, September 13, 2017

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page. Archived versions of the presentations will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists for nearly 30 years, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite[®] technologies, including VelocImmune[®] which yields optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:

Investor Relations
Manisha Narasimhan, Ph.D.
914.847.5126

manisha.narasimhan@regeneron.com

Corporate Communications
Hala Mirza
914.847.3422

hala.mirza@regeneron.com

View original content:<http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-300512368.html>

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media